Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients
Nanobiotix’s Radio-Enhancer NBTXR3 Is Being Tested In Multiple Indications
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
You may also be interested in...
The CE mark will make Hensify nanoparticle radioenhancers available in 27 European countries. Hensify is the brand name for NBTXR3, an aqueous suspension of crystalline hafnium oxide nanoparticles, approved specifically for treating locally advanced soft-tissue sarcoma.
Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.
Adequate funding and joined-up global cooperation are two top priorities needed to combat COVID-19, a panel of pharma executives told this year’s BIO-Europe Spring.